Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Videos|June 9, 2014
Research into the Monoclonal Antibody GC33 for HCC
Author(s)Ghassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).
Advertisement
Clinical Pearls
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).
- GC33 is a humanized monoclonal antibody against GPC3 that is frequently expressed in HCC.
- In aphase Ib dose escalation study, GC33 was looked at in combination with sorafenib. Though GC33 showed questionable tolerability, the agent will be looked at with a biomarker component in a future trial.
- Aphase II triallooking at GC33 in previously treated patients with HCC was also negative.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
2
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
5